Corporate PresentationFEB 2019

1

iSTAR Medical

• Private VC-backed company based in Belgium

• Lead product MINIject™ completed enrolment of

First-In-Human clinical trials with results presented

at ESCRS 2018

MINIject

• Implanted in supraciliary space

• Anti-fibrotic, soft, conforming to eye shape

• Safe

• Significant and sustained performance

• Low post-operative patient management

The next generation

MIGS made of anti-

fibrotic medical grade

silicone STAR material

2

Key Messages

STAR® material

ISO

13485

History of iSTAR Medical

3

2011STARflo

(Ab externo GDD)

First In Human

2013Series A financing

€4 Mln

2014STARflo

First multicentre

clinical trial

2016Series B financing

€10 Mln

2010iSTAR Medical founded

2016MINIject (MIGS)

Design finalised

2017MINIject

First In Human

2011Grants from

Belgium

Region

Scientific & Clinical Advisory Group

Andrew Marshall, Ph.D.

Healionics, Seattle, USA

Christophe Baudouin, MD, Ph.D.

Paris, France

Steven Vold, MD

Fayetteville, Arkansas, USA

Murray Johnstone, MD

Seattle, USA

Ike Ahmed, MD

Toronto, Canada

Norbert Pfeiffer, MD, Ph.D.

Mainz, Germany

Philippe Denis, MD, Ph.D.

Lyon, France

Julian Garcia Feijoo, MD, Ph.D.

Madrid, Spain

Antonio Fea, MD, Ph.D.

Torino, Italy

Global top

leading experts

advising

company at

each step of its

progression

Christoph Hirneiss, Ph.D.

Munich, Germany

4

Board of Directors and Management Team

Philippe Degive

• Representative of Société Régionale d'Investissement de Wallonie (“SRIW”)

• Current and past board memberships: one Therapeutics, Promethera Biosciences,

Ogeda, Cardio Life Research

David Guyer, MD

• Co-Founder & Chairman of Ophthotech Corp.

• Previously: SV Life Sciences. Co-founder of Eyetech Pharmaceuticals, Inc.,

• B.S. from Yale College & M.D. from Johns Hopkins

Max Maginness

• President and co-founder, Healionics Corporation

• Formerly with Siemens Medical, ATL (now Philips Ultrasound) and subsidiaries of

CIBA-Geigy managing multiple new product development and technology transfer

projects

Marc Nolet de Brauwere

• CEO of PhysIOL (cutting-edge IOLs)

• Current board membership: Bone Therapeutics, Cardiatis, Mymicroinvest, Endo

Tools Therapeutics, Biotech Coaching and Aliaxis

Katya Smirnyagina

• Partner, Capricorn Health-Tech Venture Fund

• Formerly with Alta Partners

• Current and past board memberships: Adocia, Confo Therapeutics, Nexstim,

Ablynx, Cerenis Therapeutics, Innate Pharma and Kiadis Pharma

Marty Wax, MD

• CMO and Executive VP of R&D at PanOptica, Inc.

• Formerly VP and Head of Discovery Research and Pre-Clinical Sciences at Alcon

• Clinical Professor of Ophthalmology and Visual Sciences at Rutgers Medical School

in Newark, N.J.

Michel Vanbrabant, CEO

• 20+ years of experience in Medical Technology

• Held several international positions at leading MedTech companies including

Guidant Inc. (now Boston Scientific) and St.Jude Medical

• Experience in several start-up organisations with a focus on go-to market strategy

and implementation

Eugene Smyth, CFO

• 20+ years as head of finance in quoted and privately owned international companies

• Experience with early stage companies, VC investors and M&A

• Formerly with PWC, Medtronic, InControl (acquired by Guidant) and Guidant

Zubair Hussain, Regulatory & Clinical Affairs

• 20+ years experience in Regulatory, Quality, Compliance and Clinical Affairs for

Pharmaceutical and Medical Device companies including in Vision care

• Formerly with Pfizer, Alcon, Ipsen

Dan Scherrer, Operations

• 20+ years experience in Operations, Product Development and Supply Chain

Management for Medical Device, Food and Electronics.

• Formerly with DePuy Spine (JNJ), Synthes, Biwi

Cecile Roy, Manufacturing

• 7 years of research experience with bio-polymeric products for drug delivery

applications

• Co-inventor of the MINIject device

Bo

ard

of

Dir

ect

ors

Man

ag

em

en

t Team

Michel Lussier, Chairman of the Board• CEO of Metronom Health, Chairman of Celyad

• Formerly a senior executive with Medtronic and Volcano

Ch

air

CEO

5

Associated with elevated Intraocular Pressure

(IOP) in most cases

Proven therapeutic options aim at lowering

IOP

Progressive, sight-

threatening disease,

largely asymptomatic

Second cause of

blindness after macular

degeneration

worldwide22

6

Glaucoma

Sources:

1. Market Scope estimates for Glaucoma prevalence (September 2016)

2. WHO/NMH/PBD/12.01 – Global data on visual impairments 2010 & Glaucoma Devices: Progress On

Multiple Fronts, Elsevier Business Intelligence, April 2013

>80 million

people

>90 million

people 1

2016 2021

Blocked drainage

canal builds up

fluid

Excess fluid increases

pressure which

damages optic nerve

The STAR® anti-fibrotic material

7

• Medical grade silicone with precision-pore geometry

• Soft, flexible, tissue-friendly

Developed at the University of Washington, Seattle, USA

iSTAR has exclusive IP rights in Ophthalmology to the STAR® anti-fibrotic material

Pore Throat

The STAR® anti-fibrotic material

Rabbit Study, Supraciliary Placement – 6m Follow Up

8

IrisCornea

Sclera

Choroid

STAR

implant

Retina

No Encapsulation

observed as shown by the

absence of a continuous

surrounding fibrous

capsule, nor continuous

macrophage, nor a

continuous fibroblast layer

Exceptional

Biointegration

of the device with

surrounding tissue

colonizing the porous

structure while preserving

in vivo drainage efficacy

Source:

Prof. Nathalie Collignon (CHU of Liège, Liège, Belgium); In-

vivo: CER Groupe (Marloie, Belgium); Histology: GIGA-ULg

Immunohistology Platform (University of Liège, Liège,

Belgium). March 2013.

iSTAR Product Pipeline

9

Feasibility study complete

Multi-center Study in

progress

>100 patients implanted

First-in-Human Study

completed

CE-marking Study

in progress

STARflo

MINIject

STAR®

anti-fibrotic material Ab Externo

Implant

MIGS

Served as a proof of concept for the STAR material

→ COMMERCIAL PRODUCT

• Micro-invasive technology which is safe and

implanted in a single-step procedure

• Entirely made of proprietary anti-fibrotic

STAR material

• Designed for significant and sustained IOP

reduction

• Targeting the supraciliary space - no bleb

formation

• Strong IP around material, device design

and implantation method

• Developed in close collaboration with world

leading KOLs – understanding real patient

needs

The next

generation MIGS

made of

anti-fibrotic

STAR material

10

MINIject

MINIject™

The MINIject™ Glaucoma Drainage System

11

• Ergonomic shape

for optimal grip

and precision

Handle Shaft

• Pre-loaded with implant

• Wheel release

mechanism

• Delivery through a small

corneal incision of

2.0mm.

• Can be performed by

cataract and glaucoma

surgeons.

Targeting the supraciliary space - Avoiding bleb formation

• Positive one year data at WGC 2019

• Safety profile continues to look very

promising - ECD side effects not

expected due to material properties and

proper placement in anterior chamber

• Performance data supports utility and patient acceptance being excellent for the vast majority of mild to moderate glaucoma patients

The next generation

MIGS made of anti-

fibrotic medial grade

silicone STAR material

12

MINIject: Summary

MINIjectTM

Company Milestones

13

H1-2018MINIject

Results from FIH

Multi-centre

clinical trial

2016Series B financing

€10 Mln

H2-2019MINIject

IDE Filing;

Results from

European trial

H1-2017MINIject

First Patient

in FIH Study

✓

✓

H1-2019Next financing round

H1-2020MINIject

CE-marking

✓